Study Type
Interventional - Device
completed
The objective of PIAAF SCREEN AF was to offer primary care patients, aged 75 years and older, new technologies to detect atrial fibrillation (AF) using a wearable ECG patch and a blood pressure machine that has the ability to detect AF.
The aim was to establish a practical and cost-effective screening strategy that could be easily applied in primary care for early detection and treatment of AF. The SCREEN-AF trial is a Canadian multicenter study of atrial fibrillation (AF) screening being conducted in a home-based setting.
Primary outcome:
The new diagnosis of ECG-confirmed atrial fibrillation or flutter within six months post-randomization.
Co-Principal Investigators, with Jeff Healey of PHRI, were:
- Rolf Watcher, University of Goettingen
- Noah Ivers, Women’s College Hospital
- David Gladstone, Sunnybrook Hopsital
- Russell Quinn, Libin Cardiovascular Institute of Alberta
Study Design
Cohort study
NO. of Countries
2
NO. of Sites
32
NO. of Participants
856
Study Period
2015 - 2020
Sponsor
PHRI
Jeff Healey
Senior Scientist
Jeff Healey
Senior Scientist
Jeff Healey is a Cardiologist/Electrophysiologist and Professor of Medicine at McMaster University. He is Yusuf Chair and Director of Cardiology at McMaster University. He is the chair of the Canadian Stroke Prevention and Intervention Network (CSPIN) and past chair of the Canadian Atrial Fibrillation guidelines committee. He is also on the steering committee of the international AF Screen organization.
Healey was the lead author of the ASSERT trial that demonstrated the increased stroke risk associated with sub-clinical atrial fibrillation (New England Journal of Medicine 2012), and the principal investigator of the ARTESIA trial, which demonstrated that anticoagulation with apixaban reduced the risk of stroke in patients with sub-clinical atrial fibrillation New England Journal of Medicine 2023). He is also the principal investigator of the LAAOS-4 trial, evaluating the role of left atrial appendage occlusion on top of NOAC therapy for prevention of stroke in high-risk individuals with atrial fibrillation.
Tara McCready
Program Director
Tara McCready
Program Director
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
Alex Grinvalds
Project Manager
Alex Grinvalds
Project Manager
Alex Grinvalds has more than 15 years experience in clinical research, of which 13 have been at PHRI. He has worked on randomized studies, device trials and numerous registries. Currently, Alex is working on studies involving patients with heart failure and arrhythmias.
Alex holds a Bachelor of Science degree from Queen’s University and a Certificate in Clinical Research from Humber College.
Canadian Institutes of Health Research (CIHR)
Canadian Stroke Prevention Intervention Network (C-SPIN)
Boehringer Ingelheim
Heart and Stroke Foundation
iRhythm Technologies Inc. (grant in kind)
completed
PIAAF Family Practice
Arrhythmia & Heart Failure
The objective of the PIAAF Family Practice study was to finnd Atrial Fibrillation (AF) among...
completed
PIAAF Pharmacy
Arrhythmia & Heart Failure
PIAAF Pharmacy was a Canadian multicentre study of atrial fibrillation (AF) screening in the community...
